| SOXS 1.79 4.07% | NVDA 177.19 -4.16% | ONMD 1.02 44.60% | NFLX 96.24 13.77% | JEM 0.096 3.90% | ENSC 0.6232 57.77% | BYND 0.9456 15.32% | PLUG 1.79 -6.28% | SOFI 17.76 -7.02% | NVD 7.53 8.50% | TZA 6.23 5.06% | NU 14.98 -0.53% | DUST 3.54 -3.50% | BITO 9.06 -2.78% | EOSE 5.695 -15.50% | XLF 51.43 -2.04% | BAC 49.83 -4.72% | AAL 13.07 -6.24% | MARA 8.94 5.80% | VEEA 0.5071 17.33% | SPY 685.99 -0.48% | SOXL 62.77 -3.93% | SLV 84.99 5.64% | XWEL 1.49 9.56% | QQQ 607.29 -0.32% | ONDS 10.08 -3.54% | BHAT 0.0495 -11.13% | PSKY 13.51 20.84% | INTC 45.61 0.33% | F 14.095 -2.19% | AAPL 264.18 -3.21% | XLE 55.92 1.58% | TQQQ 49.52 -1.06% | TSLA 402.51 -1.49% | HYG 80.72 -0.16% | TSDD 9.18 2.91% | TSLL 14.7 -3.10% | BATL 5.52 33.01% | RKT 18.19 2.36% | RXT 1.95 -14.47% | TLT 90.82 0.61% | TSLS 5.64 1.62% | WBD 28.17 -2.19% | PATH 10.73 0.14% | CRWV 79.56 -18.51% | IBIT 37.19 -2.80% | LQD 111.68 -0.04% | SOUN 8.6015 -4.21% | PLTR 137.19 0.92% | CPNG 19.08 1.98%

Encompass Health Corporation (NYSE:EHC) Insider Transaction and Financial Performance Overview

Encompass Health Corporation (NYSE:EHC) is a prominent player in the healthcare sector, specializing in inpatient rehabilitation services across the United States. The company is known for its high clinical quality and efficient capital management. Encompass Health's strategic market expansion is supported by favorable demographic trends and regulatory barriers, which contribute to its sustainable double-digit EBITDA growth.

On February 10, 2026, Patrick William Tuer, the Executive Vice President and Chief Operating Officer of Encompass Health, sold 2,804 shares of the company's stock at $107.62 each. This transaction leaves Tuer with 16,042 shares. Such insider transactions can provide insights into the executive's perspective on the company's future performance.

Encompass Health's financial performance is robust, as evidenced by its fourth-quarter 2025 results. The company reported an adjusted EPS of $1.46, a 24.8% increase from the previous year, surpassing the Zacks Consensus Estimate by 13.2%. Net operating revenues rose to $1.5 billion, marking a 9.9% year-over-year improvement. This growth is driven by increased net revenue per discharge and a rise in the number of discharges.

The company's financial metrics further highlight its strong position. With a P/E ratio of 19.29, investors are willing to pay $19.29 for every dollar of earnings. The price-to-sales ratio of 1.85 and enterprise value to sales ratio of 1.88 reflect the market's valuation of the company. Encompass Health's low debt-to-equity ratio of 0.08 indicates a conservative approach to leveraging, enhancing its financial resilience.

Encompass Health's operational leverage is bolstered by owning 79% of its real estate and efficient hospital development. The company's current ratio of 1.08 demonstrates its ability to meet short-term liabilities. As highlighted by Zacks Investment Research, Encompass Health is considered a strong growth stock, with the Zacks Style Scores aiding investors in identifying stocks with high short-term market outperformance potential.

Published on: February 10, 2026